November 7, 2019 11:10 AM EST
R&D

De­clar­ing topline PhI­II win, Take­da re­vives block­buster hopes for its trou­bled mul­ti­ple myelo­ma drug

Jason Mast

Editor

Five months af­ter dis­mal tri­al re­sults con­vinced Take­da to scrap an en­tire Phase III pro­gram for their mul­ti­ple myelo­ma drug Nin­laro, the Japan­ese gi­ant …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times